VEGFA and cancer: Bevacizumab, a humanized monoclonal antibody blocking the binding of vascular endothelial growth factor (VEGF) ligands to their receptors, was the first anti-VEGF agent approved by the U.S. Food and Drug Administration for cancer patients [152].